DSDeborah Denisse Gaibor Santos

Deborah Denisse Gaibor Santos

*This is an algorithmically generated author record based on publicly available information.

Deborah Denisse Gaibor Santos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polycystic Ovary Syndrome: A Therapeutic Challenge

    by María Fernanda Calderón León, Gabriel León San Miguel, Deborah Denisse Gaibor Santos, Rogger Isaac Chinga Acuña, Juan Carlos Suárez Fernández, Andrea Patricia Chancay Mendoza, César Oswaldo Loor Loor, Viviana Carolina Torres Vélez, Liliana Carolina Torres Vélez, Sonnia Paola Diaz Cepeda

    It is often a therapeutic challenge to manage polycystic ovary/ovarian syndrome (PCOS), as it is a pathology that affects both the metabolic and endocrine systems, generating problems associated with insulin resistance, obesity, and biopsychosocial problems mainly in adolescents and women in the reproductive stage. It affects between 5% and 18% of women of childbearing age. Its etiology is heterogeneous, and its definitive cause is still unknown. Therefore, treatment will depend on each patient’s symptoms and individual preferences. It is a common cause of anovulatory infertility in 75% of cases. The objective of this research was to determine the therapeutic challenges of PCOS, for which we reviewed high-level scientific medical articles published in databases such as PubMed, Cochrane, Latindex, Elsevier, Google Scholar, and Embase, concluding that symbiotic supplementation improves several clinical and laboratory aspects of PCOS, including an improvement in hyperandrogenism and lipid profile. In patients with PCOS resistant to treatment with clomiphene citrate (CC), the addition of human chorionic gonadotropin (HCG) at low doses would be an effective method to improve ovulation and, therefore, fertility. The combination of letrozole and clomiphene is superior to either drug separately for ovulation induction in PCOS. Surgical treatment is an option for patients resistant to medical treatment and is performed by laparoscopic or transvaginal ovarian drilling.


  • Open Access

    Alteration of Fetal Growth

    by Maria Fernanda Calderon Leon, Deborah Denisse Gaibor Santos, Diego Mauricio Cabrera Moyano, María Eugenia Ugarte Vega, Priscilla Eliana Robles Ordoñez, Mónica Piedad Moran Ayala, Gabriel Leon San Miguel, Jeaneth Paola Haro Fernández, Maritza Janneth Montesdeoca Samaniego, Javier Aquiles Hidalgo Acosta

    Fetal growth is a process that is not easy to assess and is regulated by multiple mechanisms that depend on many fetal, placental, and maternal factors. The birth weight percentile compared to the estimated gestational age reveals lower gestational ages for women and higher gestational ages for men in certain geographic areas such as Africa, with differences in comparison with the world population. The alteration in fetal growth is related to several perinatal complications such as intrauterine death, increased cesarean section, maternal-neonatal injuries, and shoulder dystocia. Among the main manifestations of fetal growth disturbance is intrauterine fetal growth restriction, which affects approximately 3–7% of all pregnancies and is defined as a condition in which the fetus fails to achieve the growth determined by its genetic makeup. Its diagnosis requires an estimated fetal weight by ultrasound lower than the 10th percentile for gestational age. The most outstanding maternal risk factor for fetal growth disturbance is maternal body mass index, where obesity predominates. Asymmetric or type II intrauterine growth restriction is more frequent in the second trimester of pregnancy.